Paul-Ehrlich-Institut

Coronavirus and COVID-19

COVID-19 Vaccines

Overview of authorised Vaccines

Comirnaty

Comirnaty is a mRNA vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 21 December 2020. The authorisation holder is BioNTech Manufacturing GmbH.

Product Information

Product Information: Comirnaty (incl. vaccine formulation for children aged 5-11 years from page 39)
European Public Assessment Report: Comirnaty
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Spikevax - COVID-19 Vaccine Moderna

Spikevax (COVID-19 Vaccine Moderna) is a mRNA vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 6 January 2021. The authorisation holder is Moderna Biotech Spain, S.L..

Product Information

Product Information: Spikevax (COVID-19 Vaccine Moderna)
European Public Assessment Report: Spikevax (COVID-19 Vaccine Moderna)
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

COVID-19 Vaccine Janssen

COVID-19 Vaccine Janssen is a vector vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 11 March 2021. The authorisation holder is Janssen-Cilag International NV.

Product Informaton

Product Information: COVID-19 Vaccine Janssen
COVID-19 Vaccine Janssen European Public Assessment Report
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Vaxzevria - COVID-19 Vaccine AstraZeneca

Vaxzevria is a vector vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 29 January 2021. The authorisation holder is AstraZeneca AB, Sweden.

Product Information

Product Information: Vaxzevria (COVID-19 Vaccine AstraZeneca)
EPAR: Vaxzevria (COVID-19 Vaccine AstraZeneca)
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Nuvaxovid

Nuvaxovid (NVX-CoV2373) is a protein-based vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 20 December 2021. The authorisation holder is Novavax CZ a.s..

Product Information

Product Information Nuvaxovid
European Public Assessment Report: Nuvaxovid

Chronology

Vaccination Recommendations

17th Update of the STIKO vaccination recommendations from 20 January 2022 (German Only)

Vaccines in Development or Authorisation

WHO - Draft Landscape of COVID-19 Candidate Vaccines
COVID-19 Vaccines – Overview of Vaccine Types Authorised or in the Process of Authorisation in Europe

Content

  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations
  4. FAQ Coronavirus
  5. Biomedicines
  6. Safety of COVID-19 Vaccines
  7. Research Work
  8. SARS-CoV-2 Test Systems